Welcome to our dedicated page for Novartis SEC filings (Ticker: NVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Novartis AG (NVS) SEC filings page on Stock Titan provides access to the company’s US regulatory disclosures, including Form 20‑F annual reports and Form 6‑K current reports. As a foreign private issuer based in Basel, Switzerland, Novartis uses these filings to communicate with US investors about financial performance, capital markets activity, clinical and regulatory milestones, and strategic transactions.
Form 6‑K reports frequently incorporate press releases on key events such as US Food and Drug Administration (FDA) approvals, major trial readouts and business development deals. Recent 6‑K filings have included announcements of FDA approvals for Rhapsido (remibrutinib) in chronic spontaneous urticaria, Vanrafia (atrasentan) for reduction of proteinuria in primary IgA nephropathy, Fabhalta (iptacopan) for C3 glomerulopathy, Leqvio (inclisiran) label expansion for hypercholesterolemia, and Itvisma (onasemnogene abeparvovec‑brve) for spinal muscular atrophy in older children, teens and adults. Other 6‑K filings detail positive Phase III results for ianalumab in Sjögren’s disease, multi‑asset collaborations, and the planned acquisition of Avidity Biosciences.
Investors can also find financial information in Novartis filings, such as quarterly financial reports, constant‑currency sales guidance and core operating margin disclosures. Certain 6‑K filings cover debt offerings by Novartis Capital Corporation, including terms agreements and forms of guaranteed debt securities for various note maturities, which are incorporated into the company’s shelf registration statements.
Stock Titan enhances these filings with AI‑powered summaries that explain the significance of each document in clear language. Users can quickly understand how a new 6‑K about a clinical trial result, an FDA decision, or a strategic acquisition may relate to Novartis’s pipeline and growth outlook. The filings page updates as new documents are posted to EDGAR, helping users follow NVS regulatory communications in near real time. While insider transaction details for Novartis are reported under applicable rules, this page focuses on the company’s primary SEC submissions, including 20‑F annual reports, 6‑K current reports, and related exhibits.
A holder of the issuer’s American Depositary Shares has filed a notice of planned resale under Rule 144. The filing covers 30,743 American Depositary Shares, with an aggregate market value of 4,960,276.69, to be sold through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 02/12/2026. These shares were acquired on 01/29/2026 via restricted stock vesting as compensation from the issuer. The filing notes that shares of the same class outstanding total 1,908,151,679.
An affiliate of the issuer has filed a notice of proposed sale covering 7500 American Depositary Shares, to be sold through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 02/09/2026 and an aggregate market value of 1171575.75.
The securities relate to a larger base of 1908151679 shares outstanding. The 7500 shares were acquired on 01/29/2026 via restricted stock vesting from the issuer as compensation, and this notice confirms the holder’s representation that they are not aware of undisclosed material adverse information about the issuer.
Novartis furnished a report on Form 6-K that provides investors with access to its latest annual information. The filing submits the Novartis Annual Report 2025 and the Report on Nonfinancial Matters 2025 as exhibits, making these documents officially available under U.S. securities law for foreign private issuers.
Novartis reported solid 2025 results with higher sales, profits and cash generation. Full‑year net sales reached USD 54.5 billion, up 8% at constant currencies, driven by strong volume growth partly offset by generic competition and pricing pressure.
Profitability improved meaningfully. Operating income rose to USD 17.6 billion (up 21%), while core operating income increased to USD 21.9 billion, lifting the core margin to 40.1% of net sales. Free cash flow was USD 17.6 billion, up 8%.
Key growth brands such as Kisqali, Kesimpta, Pluvicto, Cosentyx and Scemblix delivered strong double‑digit growth, and the pipeline advanced with new approvals and positive Phase III results in oncology, immunology and rare diseases. The Board proposes a dividend of CHF 3.70 per share, a 5.7% increase, and continued large share repurchases reduced shares outstanding by 66.9 million, contributing to a 22% rise in EPS to USD 7.21.
Novartis AG files its Form 20-F annual report describing its global pharmaceuticals business, 2025 performance context, and extensive risk profile. The company reports using IFRS in US dollars and had 1 908 151 679 ordinary shares outstanding as of year-end.
The report highlights strategic risks from global pricing and reimbursement pressure, including US measures such as the Inflation Reduction Act and “maximum fair price” agreements, and notes the loss of US exclusivity for Entresto in July 2025. It stresses dependence on successful R&D, protection of intellectual property, and competitive product launches.
Novartis discusses recent acquisitions (including Anthos Therapeutics, Regulus Therapeutics and Tourmaline Bio) and integration risks, as well as challenges in implementing AI, major IT programs, and managing cybersecurity, data privacy and complex supply chains. The company discloses USD 27.9 billion of non-current financial debt and USD 5.6 billion of current financial debt, and outlines exposure to geopolitical, macroeconomic, climate, tax and regulatory changes.
Novartis AG has filed proxy-related materials describing its proposed acquisition of Avidity Biosciences, Inc. through a merger in which Novartis would indirectly acquire all outstanding Avidity shares. The transaction is linked to a planned spin-off or sale of Atrium Therapeutics, Inc. (“SpinCo”) from Avidity.
Avidity will prepare and deliver a definitive proxy statement and proxy card to its stockholders in advance of a special meeting to vote on the transactions. The materials emphasize that stockholders should read the definitive proxy statement and related SEC filings because they will contain important information about the deals and the parties involved.
The communication explains that Novartis, Avidity, SpinCo and certain of their directors, officers and employees may be considered participants in the proxy solicitation, and refers investors to existing SEC filings for details on their interests. It also includes extensive forward-looking statements language, noting that completion of the transactions is subject to customary closing conditions, including regulatory approvals and approval by Avidity stockholders, and highlighting risks such as potential delays, higher-than-expected costs, competing offers, business disruption and possible stockholder litigation.
Novartis AG has filed proxy materials related to its proposed acquisition of Avidity Biosciences, Inc., which will be paired with a spin-off or sale of Atrium Therapeutics, Inc. (SpinCo). An internal message to Avidity employees explains that, following closing of the transaction, Stephen Moran, currently a Novartis executive, is expected to become Managing Director of Avidity Biosciences and will work with Avidity’s leadership to preserve its culture, AOC platform and pipeline.
The communication emphasizes that until closing, Novartis and Avidity remain separate companies, with no changes to existing structures or reporting lines. It also notes that Avidity will send a definitive proxy statement and proxy card to its stockholders ahead of a special meeting to vote on the transactions, and urges investors to read that document when available. Extensive forward-looking statement language highlights that completion of the deal, the SpinCo separation and expected benefits are subject to risks, including regulatory and stockholder approvals and potential business disruptions.
Novartis AG announced that the US FDA has approved Itvisma (onasemnogene abeparvovec-brve), the first and only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA) who have a confirmed SMN1 gene mutation. Itvisma delivers a one-time, fixed intrathecal dose that does not need to be adjusted for age or body weight and is designed to replace the missing or defective SMN1 gene.
The approval is supported by Phase III STEER and Phase IIIb STRENGTH studies, where Itvisma showed statistically significant improvement and stabilization in motor function over 52 weeks with a safety profile consistent across both trials. The therapy is intended to reduce reliance on chronic SMA treatments and will be available in the US in December, with Novartis offering patient support services to assist with access and insurance navigation.
Novartis AG updated its medium-term outlook, projecting a
The company now counts eight de‑risked, in‑market assets each targeting